Valiant Laborato

Why is Valiant Laboratories Ltd falling/rising?

As of 10-Aug, Valiant Laboratories Ltd's stock price is rising to 68.35, reflecting a 4.99% increase, supported by strong recent performance and positive market trends. Despite a decline in investor participation, the stock remains bullish, trading above key moving averages.

As of 10-Aug, Valiant Laboratories Ltd's stock price is rising, currently at 68.35, reflecting a change of 3.25 (4.99%) increase. This upward movement is supported by several factors. Over the past week, the stock has outperformed the Sensex, gaining 10.24% compared to a slight decline of 0.12% in the benchmark index. Additionally, the stock has shown a strong performance over the last three days, with a total increase of 10.69% during this period. <BR><BR>Today, the stock opened with a gain of 4.99%, reaching an intraday high of Rs 68.35. It has maintained this price without any fluctuations, indicating strong buying interest. Furthermore, the stock is trading above its 5-day, 20-day, 50-day, and 100-day moving averages, which typically suggests a bullish trend, although it remains below the 200-day moving average.<BR><BR>However, it is worth noting that there has been a decline in investor participation, with delivery volume dropping by 27.28% compared to the 5-day average. Despite this decrease in participation, the stock's liquidity remains adequate for trading. Overall, the combination of recent gains, strong performance relative to the market, and positive price movements contribute to the rising stock price of Valiant Laboratories Ltd.

Which are the latest news on Valiant Laborato?

Should I buy, sell or hold Valiant Laboratories Ltd?

When is the next results date for Valiant Laboratories Ltd?

The next results date for Valiant Laboratories Ltd is August 10, 2026.

The next results date for Valiant Laboratories Ltd is scheduled for August 10, 2026.

What does Valiant Laborato do?

Valiant Laboratories Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, formed in 1980 and converted to a Public Limited Company in 2021. As of March 2026, it reported net sales of 92 Cr and a net profit of 2 Cr, with a market cap of INR 393 Cr.

Overview:<BR>Valiant Laboratories Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Valiant Laboratories Ltd was originally formed as a Partnership Firm under the name M/s. Bharat Chemicals on October 17, 1980. It was converted into a Public Limited Company on August 16, 2021. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 92 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 393 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.04 <BR>Return on Equity: -1.06% <BR>Price to Book: 1.26<BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

How big is Valiant Laborato?

As of 10th June, Valiant Laboratories Ltd has a market capitalization of 393.00 Cr and reported net sales of 237.46 Cr, with a net loss of 3.28 Cr over the latest four quarters. The balance sheet as of March 2025 shows shareholder's funds of 234.31 Cr and total assets of 400.86 Cr.

As of 10th June, Valiant Laboratories Ltd has a market capitalization of 393.00 Cr, categorized as a Micro Cap.<BR><BR>In the latest four quarters, Valiant Laboratories reported net sales of 237.46 Cr. However, the company experienced a loss of 3.28 Cr in net profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, showing shareholder's funds of 234.31 Cr and total assets amounting to 400.86 Cr.

Who are in the management team of Valiant Laborato?

The management team of Valiant Laborato includes Velji Gogri (Chairman), Santosh S. Vora (Managing Director), Shantilal Shivji Vora (Director), Paresh Shashikant Shah (Executive Director), Sonal A Vira (Independent Director), Sandeep Gupta (Additional Non-Executive Director), and Saloni Mehta (Company Secretary & Compliance Officer).

The management team of Valiant Laborato includes the following individuals:<BR><BR>1. **Velji Gogri** - Chairman & Independent Director<BR>2. **Santosh S. Vora** - Managing Director<BR>3. **Shantilal Shivji Vora** - Director<BR>4. **Paresh Shashikant Shah** - Executive Director<BR>5. **Sonal A Vira** - Independent Director<BR>6. **Sandeep Gupta** - Additional Non-Executive Director<BR>7. **Saloni Mehta** - Company Secretary & Compliance Officer<BR><BR>If you need more specific information about any of these individuals or their roles, feel free to ask!

Who are the peers of the Valiant Laborato?

Valiant Laborato's peers include Bafna Pharma, Haleos Labs, CCME Global, Albert David, Medico Remedies, Transchem, Medicamen Biotec, Trident Lifeline, and Infinium Pharma. Valiant Laborato has below average management risk and growth, with a 1-year return of -40.70%.

Peers: The peers of Valiant Laborato are Bafna Pharma., Haleos Labs Limi, CCME Global, Albert David, Medico Remedies, Transchem, Medicamen Biotec, Trident Lifeline, and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Albert David and Medicamen Biotec, while Good management risk is found at Medico Remedies. Average management risk is noted at Haleos Labs Limi, Transchem, and the rest. Below Average management risk is seen at Bafna Pharma., CCME Global, Valiant Laborato, Infinium Pharma, and the rest. Growth is Good at Valiant Laborato, while Excellent growth is noted at Trident Lifeline. Below Average growth is found at Bafna Pharma., Haleos Labs Limi, CCME Global, Albert David, Medico Remedies, Transchem, Medicamen Biotec, and the rest. Capital Structure is Excellent at Albert David and Medicamen Biotec, Good at Bafna Pharma., CCME Global, and Medico Remedies, while Below Average is seen at Haleos Labs Limi, Valiant Laborato, Transchem, and the rest.<BR><BR>Return Snapshot: CCME Global has the highest 1-year return at 348.05%, while Albert David has the lowest at -18.28%. Valiant Laborato's 1-year return of -40.70% is lower than both. Additionally, peers with negative six-month returns include Medico Remedies, Medicamen Biotec, and Valiant Laborato.

Are Valiant Laboratories Ltd latest results good or bad?

Valiant Laboratories Ltd's latest results show strong revenue growth and a significant profit increase, but low operating margins and weak return on equity raise concerns about sustainability. Overall, the results are mixed, indicating potential but also underlying challenges for investors.

Valiant Laboratories Ltd's latest results present a mixed picture. On one hand, the company reported a significant net profit of ₹1.76 crores for Q4 FY26, which is a remarkable 124.93% increase compared to the previous quarter. Additionally, revenue growth was impressive, with net sales reaching ₹91.98 crores, reflecting a 75.33% quarter-on-quarter increase and a 59.16% year-on-year expansion.<BR><BR>However, despite these positive growth figures, the underlying profitability remains a concern. The operating margin is only 5.23%, which, while an improvement from the previous quarter's negative margin, is still quite low compared to industry standards. Furthermore, the return on equity (ROE) stands at a mere 1.60%, indicating weak capital efficiency and raising red flags about the company's ability to generate sustainable profits.<BR><BR>Moreover, the profit increase was largely driven by favorable tax adjustments rather than operational improvements, which suggests that the recent gains may not be sustainable. The company has also faced significant revenue erosion over the past two years, with a drastic decline from ₹333 crores in FY23 to ₹133 crores in FY25.<BR><BR>In summary, while Valiant Laboratories has shown some positive trends in the latest quarter, the persistent issues with profitability and capital efficiency indicate that the results are not entirely good. Investors should approach with caution, considering both the growth potential and the underlying challenges the company faces.

Is Valiant Laborato overvalued or undervalued?

As of November 17, 2025, Valiant Laborato is considered overvalued with a PE ratio of 85.70 and an EV to EBITDA of 61.56, significantly higher than its peers like Sun Pharma and Cipla, and has underperformed the Sensex with a year-to-date return of -27.77%.

As of 17 November 2025, the valuation grade for Valiant Laborato has moved from attractive to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued, with a PE ratio of 85.70, an EV to EBITDA of 61.56, and a ROE of only 1.60%. These figures suggest that investors are paying a premium for earnings and cash flow, which may not be justified by the company's financial performance.<BR><BR>In comparison to its peers, Valiant Laborato's valuation metrics stand out significantly. For instance, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Cipla is valued more attractively with a PE of 22.81 and an EV to EBITDA of 16.14. The stark contrast in these ratios highlights that Valiant Laborato is trading at a much higher valuation relative to its industry counterparts. Additionally, the company's stock has underperformed the Sensex, with a year-to-date return of -27.77% compared to the Sensex's gain of 8.72%, reinforcing the notion that the stock may be overvalued in the current market environment.

How has been the historical performance of Valiant Laborato?

Valiant Laborato has experienced a significant decline in financial performance over the past three years, with net sales dropping from 333.91 Cr in March 2023 to 133.38 Cr in March 2025, and operating profit turning from a profit of 39.95 Cr to a loss of 4.68 Cr. Total liabilities increased substantially, indicating growing financial challenges.

Answer:<BR>The historical performance of Valiant Laborato shows a significant decline in key financial metrics over the past three years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Valiant Laborato's net sales have decreased from 333.91 Cr in March 2023 to 182.06 Cr in March 2024, and further down to 133.38 Cr in March 2025. Total operating income followed a similar trend, dropping from 333.91 Cr in March 2023 to 133.38 Cr in March 2025. The company's operating profit (PBDIT) also saw a drastic decline, moving from a profit of 39.95 Cr in March 2023 to a loss of 4.68 Cr in March 2025. Consequently, profit before tax shifted from 38.14 Cr in March 2023 to a loss of 1.51 Cr in March 2025, and profit after tax fell from 29.00 Cr to a loss of 2.20 Cr in the same period. The company's total liabilities increased from 212.97 Cr in March 2023 to 400.86 Cr in March 2025, while total assets rose from 212.97 Cr to 400.86 Cr, indicating a growing financial burden. Cash flow from operating activities decreased significantly from 56.00 Cr in March 2023 to 1.00 Cr in March 2025, and the net cash outflow in March 2025 was recorded at -6.00 Cr, reflecting ongoing financial challenges.

Is Valiant Laborato technically bullish or bearish?

As of August 6, 2025, Valiant Laborato's trend is mildly bullish due to daily moving averages, but mixed signals from the weekly MACD and Bollinger Bands suggest caution despite a bullish weekly RSI.

As of 6 August 2025, the technical trend for Valiant Laborato has changed from sideways to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating a bullish signal. However, the weekly MACD remains bearish, and the Bollinger Bands are showing a mildly bearish trend on both weekly and monthly time frames. The weekly RSI is bullish, which supports the mildly bullish outlook, but the overall mixed signals from the MACD and Bollinger Bands suggest caution. The OBV is mildly bearish on the weekly but bullish on the monthly, indicating some divergence in volume trends. Overall, while there are bullish indicators, the strength is tempered by bearish signals in other areas.

Who are the top shareholders of the Valiant Laborato?

The top shareholder of Valiant Laborato is Dhanvallabh Ventures LLP, holding 46.84%. Other notable shareholders include L7 Hitech Private Limited with 2.23% and individual investors collectively owning 16.28%.

The top shareholders of Valiant Laborato include Dhanvallabh Ventures LLP, which holds the largest stake at 46.84%. The company is primarily controlled by its promoters, and there are no pledged promoter holdings. In terms of public shareholders, L7 Hitech Private Limited is the highest with a holding of 2.23%. Additionally, individual investors collectively own 16.28% of the company. There are also three foreign institutional investors (FIIs) holding a total of 0.64%.

Has Valiant Laborato declared dividend?

No Dividend History Available